AstraZeneca to present pivotal Phase III overall survival data for multiple cancer therapies at ESMO 2026

AstraZeneca is scheduled to present overall survival data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, taking place from October 23-27, 2026. These presentations will include data on sonesitatug vedotin (Sone-Ve) for gastric cancer, TAGRISSO (osimertinib) plus savolitinib for MET-driven EGFRm lung cancer, and IMFINZI (durvalumab) in combination with novel agents for bladder and small cell lung cancer. The data aims to redefine cancer treatment with innovative combinations and precision medicine.